667
Panorama Actual del Medicamento
REVISIÓN
Bibliografia
–
–
Alvarez G, Aldudo J, Alonso M, Santana S, Valdivieso
F.
Herpes simplex virus type 1 induces nuclear accumulation
of hyperphosphorylated tau in neuronal cells.
J Neurosci Res.
2012;
90(5): 1020-9.
–
–
Bateman RJ, Xiong C, Benzinger TLS, et al.
Dominantly
Inherited Alzheimer Network. Clinical and Bio-marker Chan-
ges in Dominantly Inherited Alzheimer’s Disease.
N Engl J
Med.
2012;
367(9): 795-804.
–
–
Cao C, Loewenstein DA, Lin X, et al.
High blood caffeine
levels in MCT linked to lack of progression to dementia.
J
Alzheimers Dis.
2012;
30(3): 559-72.
–
–
Damoiseuax JS, Seeley WW, Zhou J, et al.
Gender Modu-
lates the APOE
ε
4
Effect in Healthy Older Adults: Convergent
Evidence from Functional Brain Connectivity and Spinal Fluid
Tau Levels.
J Neurosci.
2012;
32(24): 8254-62.
–
–
Dolga M, Granic I, Nijholt I, et al.
Pretreatment with Lo-
vastatin Prevents N-Methyl-D-Aspartate-Induced Neurode-
generation in the Magnocellular Nucleus Basalis and Beha-
vioral Dysfunction.
J Alzheimer’s Disease
2009; 17: 327-36.
–
–
Domingo V, Montero N, Serra JA.
Terapéutica de la de-
mencia y de otros trastornos neuropsiquiátricos. En: Tera-
péutica farmacológica de los trastornos del sistema nervioso.
Programa de Actualización en Farmacología y Farmacotera-
pia.
Madrid: Consejo General de Colegios Oficiales de Far-
macéuticos;
2012.
pp. 275-300.
–
–
Gu Y, Schupf N, Cosentino SA, et al.
Nutrient intake and
plasma
β
-
amyloid.
Neurology.
2012;
78(23): 1832-40.
–
–
Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim
M.
An open-label trial of Korean red ginseng as an adju-
vant treatment for cognitive impairment in patients with
Alzheimer’s disease.
Eur J Neurol.
2008;
15(8): 865-8.
–
–
Imfeld P, Bodmer M, Jick SS, Meier CR.
Metformin, other
antidiabetic drugs, and risk of Alzheimer’s disease: a po-
pulation-based case-control study.
J Am Geriatr Soc.
2012;
60(5): 916-21.
–
–
Lee ST, Chu K, Sim JY, Heo JH, Kim M.
Panax ginseng
enhances cognitive performance in Alzheimer disease
Alzhe-
imer Dis Assoc Disord.
2008;
22(3): 222-6.
–
–
Nath S, Agholme L, Kurudenkandy FR, Granseth B,
Marcusson J, Hallbeck M.
Spreading of Neurode-gene-
rative Pathology via Neuron-to-Neuron Transmission of
β
-
Amyloid.
J Neurosci.
2012;
32(26): 8767-77.
–
–
Núñez M.
Fármacos contra el Alzheimer. En: Terapéutica
farmacológica de los trastornos del sistema ner-vioso.
Pro-
grama de Actualización en Farmacología y Farmacoterapia.
Madrid: Consejo General de Colegios Oficiales de Farmacéu-
ticos;
2012.
pp. 263-274.
–
–
Nyberg L, Lövdén M, Riklund U, et al.
Memory aging and
brain maintenance.
Trends Cogn Sci.
2012; 16(5): 292-305.
–
–
Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wen-
gel SP, Potter JF, Petty F.
Methylphenidate for apathy and
functional status in dementia of the Alzheimer type.
Am J
Geriatr Psychiatry.
2010;
18(4): 371-4.
–
–
Prieto C, Eimil M, López de Silanes C, Llanero M.
Im-
pacto social de la enfermedad de Alzheimer y otras demen-
cias 2011.
Fundación Española de Enfermedades Neuroló-
gicas
(
FEEN).
/
imp_social_alzheimer.pdf (2011).
–
–
Vigen CL, Mack WJ, Keefe RS, et al.
Cognitive effects
of atypical antipsychotic medications in patients with
Alzheimer’s disease: outcomes from CATIE-AD.
Am J Psy-
chiatry.
2011;
168(8): 831-9.
–
–
World Health Organization.
Dementia: A Pu-
blic Health Priority.
-
tions/2012/9789241564458_eng.pdf (2012).
Webs de interés
–
–
Fundación Alzheimer España.
–
–
Asociación Española de Neuropsiquiatría.
–
–
Sociedad Española de Neurología.
/
